High-Sensitivity Assays for C-Reactive Protein as a Systemic Inflammatory Marker in Assessing Asthma

Abstract
Asthma is a chronic inflammatory condition, and the main features include airway hyper-responsiveness and inflammation of the airway with the accumulation of inflammatory cells. Increased level of plasma fibrinogen and serum amyloid A suggests the involvement of systemic inflammation in asthma. C-reactive protein (CRP) is an acute-phase protein that produced mainly by hepatocytes and is an inflammatory marker. CRP levels monitoring is useful in the evaluation of early inflammation and efficacy of treatment in acute-phase illnesses. Several studies show that asthma alone can cause an increase in high-sensitivity CRP (hs-CRP) when compared with the healthy controls. Besides that, steroid-naïve patients have a higher mean value of hs-CRP levels compared with those on inhaled corticosteroid. Furthermore, studies have shown that an elevated hs-CRP level has a positive correlation with non-atopic asthma but not atopic asthma. Additionally, an increase in serum hs-CRP levels correlates with the severity of asthma. Therefore, serum hs-CRP is a useful surrogate marker to predict the severity of inflammation of the bronchus in asthma and assess the asthma status.
INTRODUCTION

Asthma is a chronic inflammatory condition where the main physiological features include reversible airflow narrowing and systemic inflammation.\(^1\) Airway hyper-responsiveness and inflammation of the airway with the accumulation of inflammatory cells are observed in mild and moderate asthma to severe asthma.\(^2\) Involvement of inflammatory cells such as neutrophils, eosinophils, mast cells, neutrophils, cytokines, and T-lymphocytes in asthma induce systemic inflammation.\(^3\) Increased level of plasma fibrinogen and serum amyloid A suggests the involvement of systemic inflammation in asthma.\(^4\) Severe inflammation and exacerbation occur in asthma due to narrowing of the airway, airway oedema, bronchial hyper-responsiveness, and hypersecretion which result from the remodeling process.\(^2\) Several studies have shown that the inflammatory process in asthma correlates with severity of disease and deterioration of pulmonary function.\(^2, 5-8\)

C-reactive protein (CRP) is an acute-phase protein that is produced mainly by hepatocytes and is an inflammatory marker.\(^9\) IL-1, IL-6, and TNF-\(\alpha\) are important cytokines that stimulate the activation of CRP.\(^7\) IL-6 is involved in phosphorylation of the transcription factor through gene activation and thus promotes the synthesis of CRP.\(^10, 11\) Besides that, IL-1\(\beta\) stimulates the transcriptional events in the presence of IL-6 which then activates CRP.\(^12\) IL-6 has growth-regulator factors which are involved in activation, growth, and differentiation of T-cells.\(^7\) Moreover, activation of CRP can stimulate the vascular smooth muscle cells to secrete more TNF-\(\alpha\).\(^13\) CRP is involved in complement activation and activation of phagocytic cells to eliminate bacteria and damaged cells.\(^7\) Increased CRP levels may indicate several conditions such as infection, cancer, and autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis, and myocardial infarction.\(^9\) CRP levels monitoring is useful in the evaluation of early inflammation and efficacy of treatment in acute-phase illnesses.\(^14\) High-sensitivity assays for CRP (hs-CRP) which measures the very low amount of CRP in the blood (below 0.2 mg/L) has been used to evaluate the systemic inflammation and prognostic marker for diabetes mellitus and cardiovascular diseases.\(^2\) A population-based study by Kony et al.\(^15\) suggested that increased CRP levels are associated with higher frequency of bronchial hyper-responsiveness and respiratory impairment due to systemic inflammation. Therefore, hs-CRP could be used to detect systemic inflammation and the severity of asthma. The purpose of this paper is to evaluate the association between hs-CRP levels and patients diagnosed with asthma.

Table 1: High-sensitivity C-reactive protein levels in patients with asthma and controls.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Asthma group</th>
<th>Healthy control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Patients (n)</td>
<td>Patients (n)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hs-CRP level (mg/L)</td>
<td>Hs-CRP level (mg/L)</td>
</tr>
<tr>
<td>Galez et al., 2006(^6)</td>
<td>Observational study</td>
<td>47</td>
<td>0.55</td>
</tr>
<tr>
<td>Kasayama et al., 2008(^5)</td>
<td>Observational study</td>
<td>329</td>
<td>0.44</td>
</tr>
<tr>
<td>Pellizzaro et al., 2010(^7)</td>
<td>Observational study</td>
<td>22</td>
<td>4.20±1.32</td>
</tr>
<tr>
<td>Kilic et al., 2012(^8)</td>
<td>Observational study</td>
<td>30</td>
<td>1.97x10(^{-6})</td>
</tr>
<tr>
<td>Razi et al., 2012(^9)</td>
<td>Observational study</td>
<td>108</td>
<td>5.47±7.33</td>
</tr>
<tr>
<td>Shimoda et al., 2015(^20)</td>
<td>Observational study</td>
<td>45</td>
<td>2.21x0.39</td>
</tr>
</tbody>
</table>

Hs-CRP: high-sensitivity C-reactive protein.
METHODS

A PubMed search was conducted using the MeSH terms “C-reactive protein” OR “systemic inflammation” AND “asthma” retrieving papers from January 2000–December 2020. Additional studies of interest were retrieved from the reference list of selected articles. The search yielded 214 original articles. The titles and abstracts of all studies were screened for their eligibility to be included in this review. A full-text manuscript was examined when the decision could not be made on the basis of the title and abstract solely. A total of 19 articles were deemed relevant and were included in this review.

C-REACTIVE PROTEIN IN PATIENTS WITH ASTHMA AND HEALTHY INDIVIDUALS

Several studies have shown that serum levels of hs-CRP are increased compared with healthy controls (Table 1).5,6,16-20 Both systemic inflammation and airway inflammation may occur in asthma due to an increase in the concentration of acute-phase protein.21 A study by Jousilahti et al. showed that acute-phase proteins of systemic inflammation such as serum amyloid A and plasma fibrinogen were positively associated with asthma prevalence.22

Additionally, the study by Büyüköztürk et al. also showed that the level of acute-phase reactant serum amyloid A was significantly higher in patients diagnosed with asthma compared to healthy controls.23 Hs-CRP measurement may be used as an inflammatory marker to assess the severity of systemic inflammation asthma.5,6,16,17,19 CRPs can activate macrophages by binding with Fc receptors for antibodies, and act on monocytes and neutrophils by interacting with CRP receptors on their surface.19 Therefore, CRP can be a useful surrogate marker to assess subclinical, airway inflammation, and systemic inflammation in asthma.5,6,16,17,19

The study by Sävykoski et al.23 suggested that serum hs-CRP levels were higher in patients with mild and moderate asthma compared to the healthy controls.23 Besides that, the study by Wu et al.24 demonstrated that hs-CRP level gradually increased in asthma of various severity from mild, moderate to severe in children.24 A population-based study by Shaaban et al.25 demonstrated that increase serum CRP levels over time were associated with a decrease in forced expiratory volume in 1 second (FEV1) and pulmonary function.25 Furthermore, Kony et al.15 showed that increased serum hs-CRP was associated with lower FEV1.15 However, the study by Ramirez26 showed no significant correlation between hs-CRP and asthma with mild severity.26

However, several other factors may contribute to the elevation of serum hs-CRP levels other than asthma.17 For example, obesity, cardiovascular diseases, atherosclerosis, diabetes mellitus, and ageing may elevate the hs-CRP levels whereas smoking cessation may reduce the hs-CRP levels.17,19 Therefore, an increase in CRP level in patients with asthma may be caused by an underlying chronic inflammatory state of the patients or infections.17 Moreover, hs-CRP levels can be affected by the interval between the beginning of the asthma exacerbation and the sample collection for measurement.27 Hence, CRP is a sensitive but non-specific marker of inflammation.28 Nevertheless, an increase in hs-CRP level in children is primarily attributed to respiratory allergic diseases because the prevalence of these risk factors is very low in children.7 Besides that, serum level C3 is elevated in children with asthma, and the serum C3 level has a positive correlation with the severity of asthma.29

Despite these confounding factors, results from several studies suggest that asthma alone can cause elevated CRP levels.6,16,17,19 CRP levels are also increased in patients with undiagnosed asthma even with the absence of pulmonary events.17

C-REACTIVE PROTEIN IN STEROID-NAÏVE ASTHMA AND INHALED-CORTICOSTEROID ASTHMA

Several studies demonstrated that steroid-naive patients have a higher mean value of hs-CRP compared to those on inhaled corticosteroid (ICS; Table 2).4,6,7,9,30-33 In a study by Takemura et al.,4 serum levels of hs-CRP in steroid-naive patients correlated positively with numbers of sputum eosinophils and negatively with indices of pulmonary function. However, no significant correlation was found between serum hs-CRP levels, pulmonary function, or sputum indices in steroid-inhaling patients.4
In a study by Zietkowski et al., serum hs-CRP levels in patients diagnosed with mild-to-moderate asthma treated with ICS was lower compared to steroid-naive mild asthma but there was no correlation with serum eosinophil cationic protein. However, the study by Allam et al. showed that serum hs-CRP level had a significant positive correlation with sputum eosinophil percentage. The contradictory results from different studies can occur due to non-compliance of medication, suboptimal doses of ICS, or development of asthma that resistant to steroids.

Decreased CRP levels in patients treated with steroids can be due to the interaction between corticosteroids with IL-1β and IL-6 which reduce the production of ILs. Corticosteroids inhibit the synthesis of IL-6 is induced by cytokines such as IL-1β and TNF-α. The study by Hashino and Nakamura demonstrated that inhaled beclomethasone dipropionate improved the symptoms of asthma and hyper-responsiveness by inhibiting the infiltration of inflammatory cells in the airway tissue. In addition, Sin et al. showed that discontinuation of inhaled fluticasone increased the serum CRP level in mild-to-moderate chronic obstructive pulmonary diseases. Therefore, based on the result of these studies, ICS should reduce the systemic inflammatory marker in asthma.

Furthermore, a study by Kasayama et al. also suggested that prolonged ICSs treatment for 3 months reduces the plasma CRP levels significantly due to the clinical effect of corticosteroids on the inflammatory process of airway tissue. Deraz et al. showed that serum hs-CRP had a sensitivity of 72% and a specificity of 93% in assessment of different grades of asthma severity and control. This study also showed that the hs-CRP levels had a negative correlation with FEV₁ following corticosteroid treatment due to improved pulmonary function parameters and decreased hs-CRP levels. In addition, the

### Table 2: High-sensitivity C-reactive protein levels in patients with steroid-naive asthma and treated with inhaled corticosteroids.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Steroid-naive asthma</th>
<th>Inhaled corticosteroid asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients (n)</td>
<td>Hs-CRP level (mg/L)</td>
<td>Patients (n)</td>
</tr>
<tr>
<td>Takemura et al., 2006</td>
<td>Observational study</td>
<td>22</td>
<td>1.30±1.5</td>
</tr>
<tr>
<td>Allam et al., 2009</td>
<td>Observational study</td>
<td>24</td>
<td>2.63±2.1</td>
</tr>
<tr>
<td>Zietkowski et al., 2009</td>
<td>Observational study</td>
<td>20</td>
<td>1.36±0.54</td>
</tr>
<tr>
<td>Deraz et al., 2011</td>
<td>Observational study</td>
<td>30</td>
<td>3.15</td>
</tr>
<tr>
<td>Girdhar et al., 2011</td>
<td>Observational study</td>
<td>30</td>
<td>48.0±60.0</td>
</tr>
<tr>
<td>Halvani et al., 2012</td>
<td>Observational study</td>
<td>30</td>
<td>3.32</td>
</tr>
<tr>
<td>Hoshino et al., 2014</td>
<td>Observational study</td>
<td>48</td>
<td>0.90</td>
</tr>
<tr>
<td>Karthikeyan et al., 2014</td>
<td>Observational study</td>
<td>18</td>
<td>0.93±1.18</td>
</tr>
</tbody>
</table>

Hs-CRP: High-sensitivity C-reactive protein.
study by Girdhar also showed that hs-CRP levels decreased after treatment in patients with asthma where the hs-CRP levels before and after treatment were 4.8±6.0 mg/dL and 2.4±5.4 mg/dL, respectively. Some studies did not show a significant decrease in hs-CRP level because of short duration and therapy, and inclusion of patients diagnosed with mild or moderate asthma where the inflammatory markers would be detected even at lower levels of inflammation. Qian et al. showed that hs-CRP is a sensitive marker only in cases of severe asthma. Patients with a BMI >25 kg/m², especially females, have a higher risk of developing moderate to severe degrees of asthma. The study by Boulet and Franssen suggested that obese patients were less likely to achieve asthma control with ICS or ICS with a long-acting β-agonist compared to patients who were non-obese. All those factors may cause only slight reduction in hs-CRP levels after treatment.

C-REACTIVE PROTEIN IN ATOPIC AND NON-ATOPIC ASTHMA

The study by O’Lafsdottir et al. suggested that higher hs-CRP levels are associated with non-allergic asthma but not in allergic asthma. Besides that, hs-CRP levels were also affected by age, BMI, and smoking. The study by Sahoo et al. also showed that increase in hs-CRP levels was observed in non-atopic asthmatics but no association of increased hs-CRP in atopic asthmatics. The mean hs-CRP levels in atopic asthma and non-atopic asthma were 2.9±2.1 mg/L and 8.3±2.5 mg/L respectively, in the study. Furthermore, the study by Butland et al., also demonstrated that hs-CRP levels had a positive correlation with non-atopic asthma but not atopic asthma.

Lack of correlation between hs-CRP and atopic asthma suggests that the mechanism underlying the bronchial hyperresponsiveness is different. The study by Lúdvíksdóttir et al. showed that atopic asthma was more hyper-responsive to adenosine 5'-monophosphate (AMP) compared to non-atopic asthma. Another study by Lúdvíksdóttir et al. showed that atopic asthma had higher levels of exhaled nitrogen oxide compared to non-atopic asthma. Moreover, the study by Amin et al. showed that the number of eosinophils, T-lymphocytes (CD3-, CD4-, CD8-, CD-25-positive cells), IL-4, and IL-5 increased more significantly in atopic asthma compared to non-atopic asthma. Furthermore, atopic asthma has a higher degree of epithelial damage compared to non-atopic asthma. Negative correlation between hs-CRP levels and atopic asthma suggest that the systemic inflammatory process in atopic asthma is low.

The study by Wood et al. demonstrated that asthmatic patients with neutrophilic airway inflammation had increased systemic inflammation. Therefore, CRP can be a systemic marker for patients with neutrophilic asthma. Moreover, the study by Ko et al., also reported that hs-CRP had a significant association with patients with asthma with high neutrophil and low eosinophils. The study also showed that hs-CRP levels were correlated with small airway obstruction in patients diagnosed with neutrophilic asthma. Inflammatory mediators results from inflammation or repair mechanisms may ‘spill-over’ into circulation which may lead to systemic inflammation. Fu et al showed that systemic inflammation in neutrophilic asthma had altered genes involved in IL-1, TNF-α/nuclear factor-κB, and Kit receptor pathways which were associated with immune response, inflammatory responses, and defense. Furthermore, Wood et al. showed that patients with neutrophilic asthma had increased receptors α for IL-8 (IL-8-RA) which are highly selective for neutrophil chemotaxis. Meanwhile, there were several studies suggested that there was no correlation between hs-CRP level with history of atopy, eosinophilia inflammation, and allergic sensitisation.

C-REACTIVE PROTEIN IN PREDICTING ASTHMA CONTROL

Four studies showed that serum hs-CRP increases with the severity of asthma and the highest among patients with poorly controlled and exacerbating asthma (Table 3). However, studies by Ramirez et al. and Sigari et al. demonstrated no significant correlation between hs-CRP levels and clinical indices of asthma control. The studies by Fujita et al. and Al Obaidi et al. classified patients to stable asthma and exacerbating asthma, the study by Ramirez et al. classified the patients according to the National Asthma Education and Prevention Program (NAEPP) control scores.
Table 3: Correlation between high-sensitivity C-reactive protein levels and asthma control.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Well-controlled asthma</th>
<th>Partly controlled asthma</th>
<th>Poorly controlled or exacerbating asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Patients (n)</td>
<td>Hs-CRP level (mg/L)</td>
<td>Patients (n)</td>
</tr>
<tr>
<td>Fujita et al., 2007</td>
<td>Observational study</td>
<td>NA</td>
<td>0.473</td>
<td>NA</td>
</tr>
<tr>
<td>Al Obaidi et al., 2013</td>
<td>Observational study</td>
<td>126</td>
<td>16.970</td>
<td>NA</td>
</tr>
<tr>
<td>Ramirez et al., 2010</td>
<td>Observational study</td>
<td>27</td>
<td>2.040</td>
<td>NA</td>
</tr>
<tr>
<td>Kilic et al., 2012</td>
<td>Observational study</td>
<td>7</td>
<td>0.700x10^-6</td>
<td>NA</td>
</tr>
<tr>
<td>Sigari et al., 2013</td>
<td>Observational study</td>
<td>59</td>
<td>10.600</td>
<td>30</td>
</tr>
<tr>
<td>Monadi et al., 2016²</td>
<td>Observational study</td>
<td>80</td>
<td>1.980±1.700</td>
<td>NA</td>
</tr>
</tbody>
</table>

Hs-CRP: High-sensitivity C-reactive protein; NA: not available.

The study by Sigari et al. classified the patients according to Global Initiative for Asthma (GINA) control and the studies by Kilic et al. and Monadi et al. classified the patients according to Asthma Control Test (ACT).

The management goals of patients diagnosed with include suppression of airway inflammation and the achievement of well-controlled asthma. ICS treatment was associated with decreased hs-CRP levels and therefore serum hs-CRP levels may be used to differentiate between poorly-controlled asthma and well-controlled asthma. However, the study by Ramirez et al. suggested that there was no correlation between hs-CRP level with wheeze, the National Asthma Education and Prevention Program (NAEPP) control score, fractional exhaled nitric oxide, and FEV₁. The study by Khalili et al. also showed that the fractional exhaled nitric oxide level was not associated with asthma control based on Asthma Control Questionnaire (ACQ). Nevertheless, a study by Hancox et al. demonstrated that CRP level had a negative correlation with FEV₁ and forced vital capacity. Moreover, two observational studies have shown that hs-CRP levels have a positive correlation with the severity of asthma. A study by Tonelli et al. also demonstrated that hs-CRP levels are significantly higher in patients with severe asthma compared to patients without any respiratory symptoms.

Several studies showed that hs-CRP can be used as a surrogate marker for evaluation and monitoring of asthma, estimation of disease severity, and response to corticosteroid therapy. The synthesis rate of CRP reaches highest at around 48 hours and the CRP level decreases rapidly after the pathology ceases. Elevation levels of hs-CRP in well-controlled asthma compared to healthy controls suggest that the continuous eosinophilic inflammation. Several studies have shown that patients diagnosed with asthma are likely to have higher CRP concentrations compared to individuals who were diagnosed formerly with asthma or never had asthma. Moreover, two studies have shown that increase levels of hs-CRP are associated with respiratory symptoms of asthma such as wheeze, dyspnoea after effort, and nocturnal cough. Therefore, patients with asthma with exacerbation or that is poorly controlled may have elevated CRP concentration compared to patients with stable asthma or healthy control.
The study by Kony et al. showed that higher frequency of bronchial hyper-responsiveness was associated with higher CRP levels while FEV₁ had a negative correlation with CRP. The study by Fujita et al., demonstrated the serum hs-CRP levels have a positive correlation with the degree of airway obstruction as measured by FEV₁/FVC. Furthermore, the study by Al Obaidi et al. showed that patients diagnosed with asthma who had frequent bronchial hyper-responsiveness or reduced FEV₁ tend to have both local inflammation in the bronchus and systemic inflammation. Therefore, increased CRP levels are associated with impairment of FEV₁, decline of lung function, and high frequency of bronchial hyper-responsiveness.

Several studies have shown that hs-CRP levels are correlated with asthma control. Therefore, hs-CRP levels can be used as an adjunct in assessment of asthma control in routine clinic follow-up since measurement is relatively simple and non-invasive. Moreover, hs-CRP can be a marker for systemic inflammation that reflects on the control of the patient’s symptoms and severity. Furthermore, hs-CRP level can also be used as a clinical indicator for dosage of ICSs and disease management. However, hs-CRP levels in some patients during asthma exacerbation remains unchanged or decreased compared with the levels during asymptomatic period. Several infectious and inflammatory conditions may alter the hs-CRP levels which may impair it’s the accuracy as an indicator for asthma control. Therefore, hs-CRP level may be used as an additional clinical marker for asthma control in routine follow-up but not during asthma exacerbation in acute settings because it is not specific. Hs-CRP can be used as a tool for monitoring the asthma status but is not recommended for the diagnosis of asthma. Further longitudinal research is required to compare the efficacy and accuracy of hs-CRP levels with other investigations such as arterial blood gas, peak flow, and pulse oximetry in assessing asthma exacerbation.

Further follow-up cohort studies are warranted by assessing asthma control periodically and measuring hs-CRP levels prospectively to confirm the correlation.

**CONCLUSION**

In conclusion, an increase in hs-CRP level in asthmatic patients suggest that asthma involves systemic inflammation rather than the location inflammation of the airway. ICS can reduce the local inflammation of the airway and systemic inflammation where the level of hs-CRP shows reduction after treatment. Additionally, a high hs-CRP level is associated with a decline in pulmonary function and increased sputum eosinophils. Moreover, increased hs-CRP level has a significant association with non-atopic asthma and severity of respiratory symptoms but not with atopic asthma. Nevertheless, serum hs-CRP is an effective surrogate marker to predict the severity of inflammation of the bronchus in asthma. Furthermore, hs-CRP can be used as a marker to assess asthma status because increased serum hs-CRP has a positive correlation with the severity of asthma. Hence, serum hs-CRP can serve as an effective marker to assess the control and severity of asthma and response to treatment.

**References**

10. Agrawal A et al. Transactivation of
C-Reactive Protein by IL-6 Requires Synergistic Interaction of CCAAT/Enhancer Binding Protein β (C/EBPβ) and Rel P50. J Immunol. 2001;166(4):2378.


43. Amin K et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med. 2000;162(6):2295-301.


